Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Cambrex sales decrease by 11.2% in first quarter 2014

Cambrex Corporation reports results for the first quarter ended March 31, 2014.

2 May 2014

CVS Caremark net revenues increase 6.3% to $32.7 billion in Q1 2014

CVS Caremark Corporation today announced operating results for the three months ended March 31, 2014.

2 May 2014

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237).

30 Apr 2014

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.

29 Apr 2014

Mylan challenges FDA's decision regarding generic drug marketing exclusivity on Celecoxib Capsules

Mylan Inc. today announced that it has filed suit against the U.S. Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex.

26 Apr 2014

Rite Aid's fourth quarter revenues increase 2.2% to $6.6 billion

Rite Aid Corporation today reported operating results for its fourth quarter and fiscal year ended March 1, 2014.

10 Apr 2014

FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States.

9 Apr 2014

Walgreens' March sales up 4.5% to $6.43 billion

Walgreens had March sales of $6.43 billion, an increase of 4.5 percent from $6.16 billion for the same month in fiscal 2013.

3 Apr 2014

Viewpoints: 'Thrice-buried' Obamacare 'looks very much alive;' Ted Cruz 'gets an earful'

Back when rate shock, website problems and lagging enrollment were threatening to unravel the new health care law before it fully took effect, I concluded a column on Obamacare's repeated near-death experiences with the following warning to conservatives: ... What isn't killed outright grows stronger the longer it's embedded in the federal apparatus, gaining constituents and interest-group support just by virtue of its existence even if it doesn't work out the way it was designed. ... the serious right-of-center alternatives to Obamacare have always included policies to expand coverage, and with a coverage expansion accomplished, Republicans may find themselves effectively forced in a more serious direction. ... wherever they go and whatever they do, they will have to deal with the reality that Obamacare, thrice-buried, looks very much alive (Ross Douthat, 3/31).

2 Apr 2014

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent").

1 Apr 2014

Viewpoints: Generic drug warnings; Medicare Advantage 'scam'

Late last year, the Food and Drug Administration proposed sensible regulations that would authorize the makers of generic drugs to update safety labels independently, without waiting for F.D.A. approval, to warn of newly discovered risks.

28 Mar 2014

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013.

21 Mar 2014

CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

In March 2012, the 1st Nextgen China was held successfully in Shanghai. FDA, USP, national institutes for Food and Drug Control and leading pharmaceutical companies from home and abroad were invited to give presentations.

12 Mar 2014

Teva launches generic Xeloda Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda is marketed by Genentech in the United States.

8 Mar 2014

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

Although there is widespread consensus among the scientific community that the composition of generic drugs is identical to that of brand name drugs, this is not the case among the public.

7 Mar 2014

Akorn's consolidated revenue for fourth quarter 2013 increases 19% to $85 million

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year-ended December 31, 2013.

3 Mar 2014

Viewpoints: The evolution of Medicare; generic drugs and patient safety; new food labels

About half a century ago, organized medicine and the hospital industry in this country struck a deal with Congress that in retrospect seems as audacious as it seems incredible: Congress was asked to surrender to these industries the keys to the United States Treasury. In return, the industries would allow Congress to pass a 1965 amendment to the Social Security Act .... We have come to know it as Medicare.

3 Mar 2014

First Edition: February 18, 2014

Kaiser Health News staff writer Jay Hancock, working in collaboration with USA Today, reports: "Congratulations. You bought insurance through one of the online Affordable Care Act exchanges, possibly after days or weeks of trying to get the site to work. Don't relax. Joining the plan is only the first challenge. Now you have to understand it. Policies sold through the online portals -- to more than 3 million people so far -- cover essential benefits and put a cap on your out-of-pocket medical costs. But you need to follow the rules" (Hancock, 2/17).

18 Feb 2014

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.

13 Feb 2014

Cambrex fourth quarter sales increase 46.3% to $103 million

Cambrex Corporation reports results for the fourth quarter and full year ended December 31, 2013.

11 Feb 2014